+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biodefence Market Report 2023-2033

  • PDF Icon

    Report

  • 197 Pages
  • January 2023
  • Region: Global
  • Visiongain
  • ID: 5806070
The Biodefence Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing R&D Investments in Developed Countries

Growing R&D investments enable pharmaceutical and biopharmaceutical companies to manufacture superior quality and technologically advanced bio-threat detection devices that should significantly impact the industry growth. Furthermore, European government also supports the R&D activities to manufacture vaccines against various diseases such as anthrax, small pox and botulism in large batches to fight infections and prevent the spread of endemic diseases. Bioterrorism attacks lead to deaths and may weaken the economy hence, government funds various pharmaceutical as well as biopharmaceutical companies that will elevate the industry growth in foreseeable future.

Increasing Awareness Regarding Bioterrorism Attacks to Propel Industry Growth

Increasing awareness regarding bioterrorism attacks in developed as well as underdeveloped economies will significantly fuel the biodefence market growth over the forecast period. Owing to the advent of internet and growing adoption of social media, news about the biological warfare in any part of the world can spread across the globe. It can cause anxiety to people located faraway and can greatly impact trade and travel. Governments in the developing countries such as Japan and India plan public awareness campaigns to raise public awareness about bioterrorism attacks. Such preventive measures undertaken by the government to combat various endemic diseases will boost industry growth in the foreseeable future.

Low Government Funding in Underdeveloped Regions Likely to Challenge Market Growth

Minimal government intervention and low R&D funding in underdeveloped regions will impede the biodefence market growth over the forecast period. Furthermore, due to poor economic development, governments and regulatory authorities in countries such as Mexico and Brazil are unable to make significant investments to promote the use of biothreat detection devices. There is a lack of awareness in developing regions about the availability of technologically advanced biothreat detection devices. Additionally, there is no established regulatory framework for biodefence devices and vaccines in underdeveloped economies. Key players that operate in the biodefence industry find it difficult to enter these countries due to changing trade policies. As a result, the distribution of tools and vaccinations used to combat bioterrorism is low in emerging regions which may hamper the Biodefence market growth.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the Biodefence Market evolving?
  • What is driving and restraining the Biodefence Market?
  • How will each Biodefence submarket grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each Biodefence submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading Biodefence Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Biodefence development projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of Biodefence development projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the Biodefence Market?
  • Where is the Biodefence Market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Biodefence Market today, and over the next 10 years:

  • Our 197-page report provides 112 tables and 107 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Biodefence Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, the new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising prices of bio-threat detection devices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

By Product

  • Vaccines
  • Anthrax
  • Small Pox
  • Botulism
  • Others
  • Biothreat detection devices
  • Assays and reagents
  • Detectors
  • Identifiers
  • Samplers
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 16 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA
The report also includes profiles and for some of the leading companies in the Biodefence Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

  • Alexeter Technologies, LLC,
  • Altimmune
  • Achaogen, Inc.
  • Alnylam Pharmaceuticals
  • ANP Technology
  • Bavarian Nordic
  • BBI Detection
  • Biofire Defense (bioMerieux SA)
  • Biosearch Technologies
  • Bruker
  • Dynport Vaccine Company
  • Electronic Sensor Technology Inc.
  • Elusys Therapeutics
  • Emergent BioSolutions Inc.
  • Ichor Medical
  • NanoLogix
  • New Horizons Diagnostic Corporation
  • PositiveID Corporation
  • Research International
  • SIGA Technologies, Inc.
  • Statera Biopharma (Cleveland Biolabs)
  • Smith’s Detection
  • Synexis Systems
Overall world revenue for Biodefence Market, 2023 to 2033 in terms of value the market will surpass US$15,922 million in 2023, this work calculates. We predict strong revenue growth through to 2033. this work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Biodefence Market, 2023 to 2033 report help you?

In summary, this 197-page report provides you with the following knowledge:
  • Revenue forecasts to 2033 for Biodefence Market, 2023 to 2033 Market, with forecasts for Type of Product, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 16 key national markets - See forecasts for the Biodefence Market, 2023 to 2033 market in North America, Europe, Asia-Pacific and Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles of the major companies involved in the Biodefence Market, 2023 to 2033.
Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Biodefence Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Biodefence Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing R&D investments by the government
3.2.1.2 Favourable government initiatives in emerging economies
3.2.1.3 Technological developments in biotechnology sector in the developed countries
3.2.2 Market Restraining Factors
3.2.2.1 Low R&D funding in underdeveloped regions
3.2.3 Market Opportunities
3.2.3.1 Increasing list of bio-threat agents
3.2.3.2 Development of advanced biotechnology products
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
4 Biodefence Market Analysis by Product
4.1 Key Findings
4.2 Product Segment: Market Attractiveness Index
4.3 Biodefence Market Size Estimation and Forecast by Product
4.4 Vaccines
4.4.1 Anthrax
4.4.1.1 Market Size by Region, 2023-2033 (US$ Mn)
4.4.1.2 Market Share by Region, 2023 & 2033 (%)
4.4.2 Small Pox
4.4.2.1 Market Size by Region, 2023-2033 (US$ Mn)
4.4.2.2 Market Share by Region, 2023 & 2033 (%)
4.4.3 Botulism
4.4.3.1 Market Size by Region, 2023-2033 (US$ Mn)
4.4.3.2 Market Share by Region, 2023 & 2033 (%)
4.4.4 Others
4.4.4.1 Market Size by Region, 2023-2033 (US$ Mn)
4.4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 Biothreat detection devices
4.5.1 Assays and reagents
4.5.1.1 Market Size by Region, 2023-2033 (US$ Mn)
4.5.1.2 Market Share by Region, 2023 & 2033 (%)
4.5.2 Detectors
4.5.2.1 Market Size by Region, 2023-2033 (US$ Mn)
4.5.2.2 Market Share by Region, 2023 & 2033 (%)
4.5.3 Identifiers
4.5.3.1 Market Size by Region, 2023-2033 (US$ Mn)
4.5.3.2 Market Share by Region, 2023 & 2033 (%)
4.5.4 Samplers
4.5.4.1 Market Size by Region, 2023-2033 (US$ Mn)
4.5.4.2 Market Share by Region, 2023 & 2033 (%)
5 Biodefence Market Analysis by Region
5.1 Key Findings
5.2 Regional Segment: Market Attractiveness Index
5.3 Biodefence Market Size Estimation and Forecast
6 North America Biodefence Market Analysis
6.1 Key Findings
6.2 North America Biodefence Market Attractiveness Index
6.3 North America Biodefence Market by Country, 2023, 2028 & 2033 (US$ Mn)
6.4 North America Biodefence Market Size Estimation and Forecast by Country
6.5 North America Biodefence Market Size Estimation and Forecast by Product
6.6 U.S. Biodefence Market Analysis
6.7 Canada Biodefence Market Analysis
7 Europe Biodefence Market Analysis
7.1 Key Findings
7.2 Europe Biodefence Market Attractiveness Index
7.3 Europe Biodefence Market by Country, 2023, 2028 & 2033 (US$ Mn)
7.4 Europe Biodefence Market Size Estimation and Forecast by Country
7.5 Europe Biodefence Market Size Estimation and Forecast by Product
7.6 Germany Biodefence Market Analysis
7.7 France Biodefence Market Analysis
7.8 UK Biodefence Market Analysis
7.9 Italy Biodefence Market Analysis
7.10 Spain Biodefence Market Analysis
7.11 Russia Biodefence Market Analysis
7.12 Rest of Europe Biodefence Market Analysis
8 Asia Pacific Biodefence Market Analysis
8.1 Key Findings
8.2 Asia Pacific Biodefence Market Attractiveness Index
8.3 Asia Pacific Biodefence Market by Country, 2023, 2028 & 2033 (US$ Mn)
8.4 Asia Pacific Biodefence Market Size Estimation and Forecast by Country
8.5 Asia Pacific Biodefence Market Size Estimation and Forecast by Product
8.6 Japan Biodefence Market Analysis
8.7 China Biodefence Market Analysis
8.8 India Biodefence Market Analysis
8.9 Australia Biodefence Market Analysis
8.10 South Korea Biodefence Market Analysis
8.11 Rest of Asia Pacific Biodefence Market Analysis
9 Latin America Biodefence Market Analysis
9.1 Key Findings
9.2 Latin America Biodefence Market Attractiveness Index
9.3 Latin America Biodefence Market by Country, 2023, 2028 & 2033 (US$ Mn)
9.4 Latin America Biodefence Market Size Estimation and Forecast by Country
9.5 Latin America Biodefence Market Size Estimation and Forecast by Product
9.6 Brazil Biodefence Market Analysis
9.7 Mexico Biodefence Market Analysis
9.8 Rest of Latin America Biodefence Market Analysis
10 MEA Biodefence Market Analysis
10.1 Key Findings
10.2 MEA Biodefence Market Attractiveness Index
10.3 MEA Biodefence Market by Country, 2023, 2028 & 2033 (US$ Mn)
10.4 MEA Biodefence Market Size Estimation and Forecast by Country
10.5 MEA Biodefence Market Size Estimation and Forecast by Product
10.6 GCC Biodefence Market Analysis
10.7 South Africa Biodefence Market Analysis
10.8 Rest of MEA Biodefence Market Analysis
11 Company Profiles
11.1 Competitive Landscape, 2021
11.1.1 BioFire Defense
11.1.2 Bruker Corporation
11.1.3 Emergent BioSolutions
11.1.4 Smiths detection
11.2 Alexeter Technologies, LLC,
11.2.1 Company Snapshot
11.2.2 Company Overview
11.2.3 Product Benchmarking
11.3 Altimmune
11.3.1 Company Snapshot
11.3.2 Company Overview
11.3.3 Financial Analysis
11.3.3.1 Net Revenue, 2017-2021
11.3.3.2 R&D, 2017-2021
11.3.4 Product Benchmarking
11.4 ANP Technology
11.4.1 Company Snapshot
11.4.2 Company Overview
11.4.3 Product Benchmarking
11.5 Bavarian Nordic
11.5.1 Company Snapshot
11.5.2 Company Overview
11.5.3 Financial Analysis
11.5.3.1 Net Revenue, 2017-2021
11.5.3.2 R&D, 2017-2021
11.5.3.3 Regional Market Shares, 2021
11.5.4 Product Benchmarking
11.5.5 Strategic Outlook
11.6 Biofire Defense (bioMerieux SA)
11.6.1 Company Snapshot
11.6.2 Company Overview
11.6.3 Financial Analysis
11.6.3.1 Net Revenue, 2017-2021
11.6.3.2 R&D, 2017-2021
11.6.3.3 Regional Market Shares, 2021
11.6.4 Product Benchmarking
11.6.5 Strategic Outlook
11.7 Biosearch Technologies
11.7.1 Company Snapshot
11.7.2 Company Overview
11.7.3 Financial Analysis
11.7.3.1 Net Revenue, 2017-2021
11.7.3.2 Regional Market Shares, 2021
11.7.4 Product Benchmarking
11.8 Bruker
11.8.1 Company Snapshot
11.8.2 Company Overview
11.8.3 Financial Analysis
11.8.3.1 Net Revenue, 2017-2021
11.8.3.2 R&D, 2017-2021
11.8.3.3 Regional Market Shares, 2021
11.8.4 Product Benchmarking
11.9 Electronic Sensor Technology Inc.
11.9.1 Company Snapshot
11.9.2 Company Overview
11.9.3 Product Benchmarking
11.10 Elusys Therapeutics
11.10.1 Company Snapshot
11.10.2 Company Overview
11.10.3 Product Benchmarking
11.10.4 Strategic Outlook
11.11 Emergent BioSolutions Inc.
11.11.1 Company Snapshot
11.11.2 Company Overview
11.11.3 Financial Analysis
11.11.3.1 Net Revenue, 2017-2021
11.11.3.2 R&D, 2017-2021
11.11.4 Product Benchmarking
11.11.5 Strategic Outlook
11.12 Ichor Medical
11.12.1 Company Snapshot
11.12.2 Company Overview
11.12.3 Product Benchmarking
11.13 NanoLogix
11.13.1 Company Snapshot
11.13.2 Company Overview
11.13.3 Product Benchmarking
11.14 New Horizons Diagnostic Corporation
11.14.1 Company Snapshot
11.14.2 Company Overview
11.14.3 Product Benchmarking
11.14.4 Strategic Outlook
11.15 PositiveID Corporation
11.15.1 Company Snapshot
11.15.2 Company Overview
11.15.3 Product Benchmarking
11.16 SIGA Technologies, Inc
11.16.1 Company Snapshot
11.16.2 Company Overview
11.16.3 Financial Analysis
11.16.3.1 Net Revenue, 2017-2021
11.16.3.2 R&D, 2017-2021
11.16.4 Product Benchmarking
11.16.5 Strategic Outlook
11.17 Alnylam Pharmaceuticals
11.17.1 Company Snapshot
11.17.2 Company Overview
11.17.3 Financial Analysis
11.17.3.1 Net Revenue, 2017-2021
11.17.3.2 R&D, 2017-2021
11.17.4 Product Benchmarking
11.17.5 Strategic Outlook
11.18 BBI Detection
11.18.1 Company Snapshot
11.18.2 Company Overview
11.18.3 Product Benchmarking
11.19 Statera Biopharma
11.19.1 Company Snapshot
11.19.2 Company Overview
11.19.3 Financial Analysis
11.19.3.1 Net Revenue, 2017-2021
11.19.3.2 R&D, 2017-2021
11.19.4 Product Benchmarking
11.20 Dynport Vaccine Company
11.20.1 Company Snapshot
11.20.2 Company Overview
11.20.3 Product Benchmarking
11.21 Research International
11.21.1 Company Snapshot
11.21.2 Company Overview
11.21.3 Product Benchmarking
11.22 Smith’s Detection
11.22.1 Company Snapshot
11.22.2 Company Overview
11.22.3 Product Benchmarking
11.22.4 Strategic Outlook
11.23 Synexis Systems
11.23.1 Company Snapshot
11.23.2 Company Overview
11.23.3 Product Benchmarking
11.23.4 Strategic Outlook
12 Conclusion and Recommendations
12.1 Concluding Remarks from
12.2 Recommendations for Market Players

Companies Mentioned

  • Alexeter Technologies, LLC,
  • Altimmune
  • Achaogen, Inc.
  • Alnylam Pharmaceuticals
  • ANP Technology
  • Bavarian Nordic
  • BBI Detection
  • Biofire Defense (bioMerieux SA)
  • Biosearch Technologies
  • Bruker
  • Dynport Vaccine Company
  • Electronic Sensor Technology Inc.
  • Elusys Therapeutics
  • Emergent BioSolutions Inc.
  • Ichor Medical
  • NanoLogix
  • New Horizons Diagnostic Corporation
  • PositiveID Corporation
  • Research International
  • SIGA Technologies, Inc.
  • Statera Biopharma (Cleveland Biolabs)
  • Smith’s Detection
  • Synexis Systems
  • AbCellera
  • AstraZeneca
  • Banbury Labels
  • Canopy Biosciences, LLC
  • Chimerix, Inc.
  • Coeptis Therapeutics, Inc
  • Cytocom
  • Dynavax Technologies Corporation
  • Encepur
  • Ensensor
  • Fulgent Pharma
  • Heat Biologics, Inc.
  • Kromek
  • Medison Pharma
  • MOLECUBES NV,
  • Neurescence Inc.
  • Novartis
  • Optimal Industrial Automation and Technologies
  • PeptiDream
  • PharmAthene
  • Prolab Instruments GmbH
  • RAVE LLC
  • Regeneron
  • Stratus
  • Valneva SE
  • Vaxart, Inc.
  • American Biological Safety Association
  • American Society for Microbiology
  • Arms Control Association
  • Asia-Pacific Biosafety Association (APBA)
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Biorisk Management Association of Kenya (BMAK)
  • Biosafety and Biosecurity Association of South Sudan (BBASS)
  • Canadian Association for Biological Safety
  • European Agency for the Evaluation of Medicinal Products
  • European Corporate Security Association (ECSA)
  • Georgian Biosafety Association (GeBSA)
  • German Biosecurity Programme
  • Infectious Disease Society of America
  • Korean Biological Safety Association
  • Malaysian Biosafety & Biosecurity Association
  • Mali Association for Biosafety & Biosecurity
  • Mexican Biosafety Association (AMEXBIO)
  • National Biosafety Association (ANBio)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Nigerian Biological Safety Association (NiBSA)
  • Office of International Health and Biodefense (IHB)
  • Tanzania Biological Safety Association (TaBSA)
  • U.S. Department of Health and Human Services
  • U.S. Department of Homeland Security
  • U.S. Government Accountability Office
  • The U.S. Food and Drug Administration (FDA)
  • World Health Organization (WHO)